Researchers at VIB and KU Leuven have identified a molecular process that allows motor neurons to maintain protein production ...

IV edaravone-treated patient had longer disease progression milestone-free time for all 6 milestones compared with control. Treatment with intravenous (IV) edaravone was associated with fewer reported ...

Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral ...

This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged ...

Some people with SOD1-ALS experienced improvements in physical function and muscle strength after three years on Qalsody, an ...

Please provide your email address to receive an email when new articles are posted on . 97 individuals with MS wore an actigraph for 3 to 7 days every 2 to 3 months for up to 24 months. The Vertical ...

A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

“[…]we have identified FGF21 as a novel biomarker in ALS that is detected in multiple compartments including muscle, spinal cord, and circulation.” In this ...

Please provide your email address to receive an email when new articles are posted on . A new analysis of an overall survival study of an investigational immunotherapy platform to treat ALS found it ...

A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...